Group 1 - The core viewpoint of the article is that Yinos (688710.SH) is planning to acquire a controlling stake in Yilinsi to enhance its integrated service solutions in the biopharmaceutical non-clinical research sector [1][2] - The acquisition aims to improve the company's upstream and downstream industry chain layout, establishing a comprehensive service system that covers drug research from early concept validation to industrial incubation [1][2] - Yilinsi, established in February 2004, specializes in clinical trial services, focusing on phases I to IV of new drug clinical trials, pharmacokinetics research, and various clinical trial management services [1][2] Group 2 - This transaction is a strategic move in response to national policies encouraging mergers and acquisitions among listed companies to enhance their core business and industry chain [2] - The acquisition will extend the company's business chain, enhance service segments, and strengthen collaboration among different business units, thereby improving the overall quality of development [2] - Yilinsi is a high-tech enterprise and has a mature system and professional capabilities in the clinical research service field, which will significantly enhance the company's comprehensive service capabilities and competitive edge in the industry [2]